Cargando…

Trastuzumab with FLOT Regimen for the Perioperative Treatment of Resectable HER2 + Advanced Gastric Cancer: A Retrospective Study

BACKGROUND: The aim of this study was to evaluate the efficacy and safety of trastuzumab, combined with the FLOT regimen, in the perioperative treatment of resectable HER-2-positive advanced gastric cancer. METHODS: Overall, 45 patients were divided into two groups; 29 patients in the experimental g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tong, Gangling, Li, Shuluan, Lin, Lin, He, Lirui, Wang, Li, Lv, Guoqing, Zheng, Ruinian, Wang, Shubin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152553/ https://www.ncbi.nlm.nih.gov/pubmed/32308484 http://dx.doi.org/10.2147/CMAR.S239420

Ejemplares similares

Cure Is Possible: Extensively Metastatic HER2-Positive Gastric Carcinoma with 5 years of Complete Remission after Therapy with the FLOT Regimen and Trastuzumab
por: Schade, Sebastian, et al.
Publicado: (2022)

Evaluation of Pathological Response Rate and Complications of FOLFOX versus FLOT Regimen in Perioperative Chemotherapy for Resectable Gastric Cancer: A Prospective Study
por: Arefpour, Amir Mohammad, et al.
Publicado: (2023)

Economic evaluation of FLOT and ECF/ECX perioperative chemotherapy in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma
por: Zeng, Hanqing, et al.
Publicado: (2022)

Efficacy and safety of FLOT regimen vs DCF, FOLFOX, and ECF regimens as perioperative chemotherapy treatments for resectable gastric cancer patients; a report from the middle east
por: Farrokhi, Pegah, et al.
Publicado: (2022)

Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma – the phase III “PREVENT”- (FLOT9) trial of the AIO /CAOGI /ACO
por: Götze, Thorsten O., et al.
Publicado: (2021)

Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group)
por: EROL, Cihan, et al.
Publicado: (2022)

An Analysis of Tolerance and Early Survival Outcomes with Perioperative Modified FLOT in Gastric Cancers
por: Bhargava, Prabhat, et al.
Publicado: (2022)

Prognostic impact of sarcopenia on immune-related adverse events in malignancies received immune checkpoint inhibitors: a systematic review and meta-analysis
por: Li, Shuluan, et al.
Publicado: (2021)

Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma—a phase II trial of the AIO study group (AIO STO 0321)
por: Tintelnot, Joseph, et al.
Publicado: (2023)

Enumeration And Characterization Of Circulating Tumor Cells And Its Application In Advanced Gastric Cancer
por: Cheng, Boran, et al.
Publicado: (2019)

Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR)
por: Dos Santos, Mélanie, et al.
Publicado: (2022)

Efficacy of Olanzapine-Triple Antiemetic Regimen in Patients with Gastrointestinal Tumor and High Risk of Chemotherapy-Induced Nausea and Vomiting Receiving Moderately Emetogenic Chemotherapy: A Retrospective Study
por: Wu, Xuan, et al.
Publicado: (2020)

Immune activity score to assess the prognosis, immunotherapy and chemotherapy response in gastric cancer and experimental validation
por: Wu, Xuan, et al.
Publicado: (2023)

MACC1 regulates PDL1 expression and tumor immunity through the c‐Met/AKT/mTOR pathway in gastric cancer cells
por: Tong, Gangling, et al.
Publicado: (2019)

HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen
por: Wu, Scott A, et al.
Publicado: (2023)

Real-World Outcomes of FLOT versus CROSS Regimens for Patients with Oesophagogastric Cancers
por: Shahnam, Adel, et al.
Publicado: (2023)

Pretreatment Modified Glasgow Prognostic Score for Predicting Prognosis and Survival in Elderly Patients with Gastric Cancer Treated with Perioperative FLOT
por: Melekoglu, Ebru, et al.
Publicado: (2023)

FLOT Neoadjuvant Chemotherapy Followed by Laparoscopic D2 Gastrectomy in the Treatment of Locally Resectable Advanced Gastric Cancer
por: Zhang, Shun, et al.
Publicado: (2020)

CD40×HER2 bispecific antibody overcomes the CCL2-induced trastuzumab resistance in HER2-positive gastric cancer
por: Sun, Weilin, et al.
Publicado: (2022)

Prognostic Impact of Sarcopenia on Clinical Outcomes in Malignancies Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Li, Shuluan, et al.
Publicado: (2021)

Is there any advantage to combined trastuzumab and chemotherapy in perioperative setting her 2neu positive localized gastric adenocarcinoma?
por: Sbitti, Yassir, et al.
Publicado: (2011)

Trastuzumab treatment after progression in HER2-positive metastatic breast cancer following relapse of trastuzumab-based regimens: a meta-analysis
por: Han, Yiqun, et al.
Publicado: (2019)

Perioperative FLOT chemotherapy plus surgery for oligometastatic esophagogastric adenocarcinoma: surgical outcome and overall survival
por: Runkel, Mira, et al.
Publicado: (2021)

Body composition dynamics and impact on clinical outcome in gastric and gastro-esophageal junction cancer patients undergoing perioperative chemotherapy with the FLOT protocol
por: Huemer, Florian, et al.
Publicado: (2022)

Effect of perioperative FLOT versus ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study
por: Moussa, Osama, et al.
Publicado: (2022)

Se maintenir à flot
por: Auer, Rebecca Ann C.
Publicado: (2021)

Targeting HER3 or MEK overcomes acquired Trastuzumab resistance in HER2-positive gastric cancer-derived xenograft
por: Zhang, Mengqi, et al.
Publicado: (2022)

Dual HER2 Blockade versus a Single Agent in Trastuzumab-Containing Regimens for HER2-Positive Early Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Yu, Liuwen, et al.
Publicado: (2020)

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
por: Soo Park, Ji, et al.
Publicado: (2017)

Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial
por: Gong, Jifang, et al.
Publicado: (2016)

1389P Real world outcomes of locally advanced gastric/GOJ cancers receiving perioperative chemotherapy with FLOT regimen during the COVID-19 pandemic: Results from a regional cancer care centre in the UK
por: Bose, S., et al.
Publicado: (2021)

Un flot ininterrompu de données
por: Ourghanlian, Bernard
Publicado: (2006)

The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
por: Maadi, Hamid, et al.
Publicado: (2018)

Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer
por: Kotani, Daisuke, et al.
Publicado: (2021)

Total neoadjuvant chemotherapy with FLOT scheme in resectable adenocarcinoma of the gastro-oesophageal junction or gastric adenocarcinoma: impact on pathological complete response and safety
por: Villanueva, Luis, et al.
Publicado: (2021)

FLOT1 promotes gastric cancer progression and metastasis through BCAR1/ERK signaling
por: Wang, Ran, et al.
Publicado: (2023)

Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma
por: GÜRLER, Fatih, et al.
Publicado: (2022)

Flot-2 Expression Correlates with EGFR Levels and Poor Prognosis in Surgically Resected Non-Small Cell Lung Cancer
por: Wen, Qiuyuan, et al.
Publicado: (2015)

Liquid biopsy: a powerful tool to monitor trastuzumab resistance in HER2-positive metastatic gastric cancer
por: Shen, Lin
Publicado: (2018)

Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study
por: Li, Qian, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_n5v3ckd224cq3fs82qaj5ho23g